Key result
High EROS score linked to ~233% higher risk of major complications in transvenous lead extraction.
Why the study?
Transvenous lead extraction carries significant complication risks, and identifying high-risk patients pre-procedurally enables interventions to be planned accordingly.
Does the ELECTRa Registry Outcome Score (EROS) appropriately risk-stratify patients undergoing transvenous lead extraction for procedural complications?
Observational
Yes
Does the ELECTRa Registry Outcome Score (EROS) appropriately risk-stratify patients undergoing transvenous lead extraction for procedural complications?
The EROS score successfully identifies patients at high risk for major procedural complications during transvenous lead extraction, aiding in pre-procedural planning.
Answers are grounded in this paper and cite their sources.
Supports EROS for pre-procedural risk stratification in lead extraction; leaves open prospective validation before routine adoption.
AIMS: Transvenous lead extraction is associated with a significant risk of complications and identifying patients at highest risk pre-procedurally will enable interventions to be planned accordingly. We developed the ELECTRa Registry Outcome Score (EROS) and applied it to the ELECTRa registry to determine if it could appropriately risk-stratify patients. METHODS AND RESULTS: EROS was devised to risk-stratify patients into low risk (EROS 1), intermediate risk (EROS 2), and high risk (EROS 3). This was applied to the ESC EORP European Lead Extraction ConTRolled ELECTRa registry; 57.5% EROS 1, 31.8% EROS 2, and 10.7% EROS 3. Patients with EROS 3 or 2 were significantly more likely to require powered sheaths and a femoral approach to complete procedures. Patients with EROS 3 were more likely to suffer procedure-related major complications including deaths (5.1 vs. 1.3%; P < 0.0001), both intra-procedural (3.5 vs. 0.8%; P = 0.0001) and post-procedural (1.6 vs. 0.5%; P = 0.0192). They were more likely to suffer post-procedural deaths (0.8 vs. 0.2%; P 0.0449), cardiac avulsion or tear (3.8 vs. 0.5%; P < 0.0001), and cardiovascular lesions requiring pericardiocentesis, chest tube, or surgical repair (4.6 vs. 1.0%; P < 0.0001). EROS 3 was associated with procedure-related major complications including deaths [odds ratio (OR) 3.333, 95% confidence interval (CI) 1.879-5.914; P < 0.0001] and all-cause in-hospital major complications including deaths (OR 2.339, 95% CI 1.439-3.803; P = 0.0006). CONCLUSION: EROS successfully identified patients who were at increased risk of significant procedural complications that require urgent surgical intervention.
No takes yet. Share an insight, caveat, or question.
Sidhu et al. (2021) conducted an observational in Transvenous lead extraction. High ELECTRa Registry Outcome Score (EROS 3) vs. Low or intermediate risk (EROS 1 or 2) was evaluated on Procedure-related major complications including deaths (OR 3.333, 95% CI 1.879-5.914, p=< 0.0001). A high EROS score (EROS 3) in transvenous lead extraction was associated with increased procedure-related major complications including death.
Synapse has enriched 10 related papers. Consider them for comparative context: